- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05350644
Inflammatory Bowel Disease(IBD), Treatment Response
Predicting Response to Medical Treatment of Inflammatory Bowel Disease (IBD) Using Single Cell Transcriptomic on Intestinal Biopsies: a Prospective Cohort Study of Personalized Medicine
Inflammatory bowel diseases (IBD) is treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF), i.e. TNF inhibitors. Up to one third of the patients do, however, not respond to biologics and little is known of the biological mechanism as a prognostic factor (possibly enabling personalised medicine). The aim of this project is to identify biomarkers that support individualized forecasting of optimized treatment outcome on these costly drugs.
This prospective cohort study will enroll IBD patients assigned for biologic treatment. At baseline (Pre-treatment), biopsies and blood is taken from each patient. Follow-up will be conducted at week 14-16 after treatment initiation (according to the current Danish standards). Evaluation of a successful treatment outcome response will - for each disease - be based on most frequently used primary endpoints; the major outcome of the analyses will be to detect differences in treatment outcome between patients with the cell expression.
The overarching goal of this project is to improve the lives of patients suffering from IBD, by providing evidence to potential biomarkers that would be likely to improve the clinical outcome.
The study is approved by the local Ethics Committee (S-20160124) and the local Data Agency (2008-58-035). The study findings will be disseminated in peer-reviewed journals, via patient associations, and presented at national and international conferences.
Study Overview
Status
Intervention / Treatment
Detailed Description
Inflammatory bowel diseases [IBD] (of which Crohn's disease (CD) and ulcerative colitis (UC) are the two most prevailed entities) is a disease of the immune system that are managed with biological agents targeting the pro-inflammatory cytokine tumour necrosis factor-α (TNF), i.e. TNF inhibitors.
Design: In this prospective cohort study disease activity prior to and after (14-16 weeks) initiation of biologic treatment will be assessed. The endpoint is the treatment outcome defined as A: Responder according to the specific criteria described below (incl. drug-continuation) or B: Non-responder (incl. drug-discontinuation due to unacceptable side effects). Whether a patient will discontinue therapy is assumed to be based on a certain degree of shared decision making between the patient and physician supported by principles from national guidelines for each patient as recommended in the respective national guidelines and laboratory data.
Setting: All patients assigned for initiation of biologic treatment at the Department of Medical Gastroenterology, Odense University Hospital from 1st of February 2022 and until 31th of December 2022 or until a minimum of 20 patients with IBD is achieved.
Clinical data consist of personal data, data on health and disease and disease activity scores. Information registered by clinicians and technicians will be transferred from paper format to electronic format using either double entry of data or automated forms processing.
Sample size considerations: We will include a limited set of patient biopsies from 20 UC patients and analyze the changes in responders versus non-responders for identifying potential predictive pathways and biomarkers. Such a strategy has recently been proven valuable for identification of biomarkers predictive of treatment response in CD with a similar number of samples as in our study All data analysis will be done in R, transparently reporting the source code used to analyze the data.
Project organization: The project is organized with a Clinical Research Group and an Analytical Research Group. The clinical group includes specialists from the medical, gastroenterological, departments that are sampling the cohort. The analytical group will perform the analyses on the biological material.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Vibeke Andersen, Prof
- Phone Number: 004521157790
- Email: vandersen@health.sdu.dk
Study Contact Backup
- Name: Zainab Hikmat, MSc
- Phone Number: 004520181720
- Email: zainab.hikmat@rsyd.dk
Study Locations
-
-
-
Aabenraa, Denmark, 6200
- Withdrawn
- Hospital of Southern Jutland
-
Odense, Denmark, 5000
- Recruiting
- Odense University Hospital
-
Contact:
- Kjeldsen
- Email: Jens.Kjeldsen@rsyd.dk
-
Odense, Denmark, 5230
- Withdrawn
- University of Southern Denmark
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- diagnosed with inflammatory bowel disease
- initiation of targeted therapy
- able to read and understand Danish
Exclusion Criteria:
- Patients with cancer
- Not mentally able to reply the questionnaire
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1. Clinical response to therapy depending on condition
Time Frame: week 14-16
|
The predefined primary endpoint will be the proportion of patients with clinical response to therapy at first clinical follow-up.
|
week 14-16
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Vibeke Andersen, Prof, University of Southern Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BELIEVE-IBD-SCT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
Clinical Trials on Primary exposure variable
-
University of Southern DenmarkOdense University Hospital; Aarhus University Hospital; University of Copenhagen and other collaboratorsCompletedAutoimmune Diseases | Inflammatory Bowel Diseases | Uveitis | Psoriasis | Spondylarthropathies | Crohn Disease (CD) | Arthritis, Rheumatoid (RA) | Arthritis, Psoriatic (PsA) | Hidradenitis Suppurativa (HS) | Colitis, Ulcerative (UC)Denmark
-
University of North Carolina, Chapel HillAmerican Psychological Association (APA); Association for Behavioral and Cognitive...Completed
-
University of LiverpoolUniversity College London Hospitals; Oswaldo Cruz Foundation; Kamuzu University... and other collaboratorsActive, not recruitingDiseases of the Nervous System | Other Specified Viral DiseasesIndia, Brazil, Malawi
-
University of MichiganNational Institute of Mental Health (NIMH)Recruiting
-
Columbia UniversityRecruiting
-
Indiana UniversityCompleted
-
Technische Universität DresdenMedical University of Vienna; University Hospital, Montpellier; University of... and other collaboratorsTerminatedAcute Lung Injury | Adult Respiratory Distress Syndrome | at Least 24 h of Controlled Mechanical VentilationGermany
-
New Mexico State UniversityUniversity of Texas; Paso del Norte Health Foundation; Brigham Young University; Ysleta Independent School District, El PasoCompletedPsychology, Social | Nutrition | Behavioral ChangesUnited States
-
Nanjing Medical UniversityCompletedDepression | Anxiety | ResilienceChina
-
VA Office of Research and DevelopmentVA Ann Arbor Healthcare System; Ralph H. Johnson VA Medical CenterCompletedPosttraumatic Stress DisorderUnited States